Antiviral drug combination for livestock

Abstract

An antiviral drug combination for livestock in the invention relates to an antiviral agent, in particular to an antiviral agent for poultry and livestock. The drug combination is composed of cyanovirin and animal IFN-alpha in mass ratio of 3:1. The invention initially applies cyanovirin to treating viral infection of poultry and livestock, and animal IFN-alpha which is prepared by gene recombination, is contained in species such as pig, chicken, cattle and the like and has high valence, high purity and antiviral effect and cyanovirin with direct antiviral effect are initially applied in a combining way; meanwhile the effect of cyanovirin is direct and rapid and the antiviral effect of IFN-alpha is wide and permanent, and the effect is better than that of single use of cyanovirin or IFN-alpha.

Description

【Technical field】 [0001] The invention relates to an antiviral agent, in particular to an antiviral agent for poultry and livestock. 【Background technique】 [0002] IFN-α is a cytokine with strong antiviral activity. It has been widely used in the treatment of human viral diseases and has become an essential therapy. For example, in the treatment of hepatitis C, IFN-α plays an irreplaceable role. Since the antiviral effect of IFN-α is indirect and works by inducing other antiviral mechanisms in the body, one of its important characteristics is that it has no virus specificity, that is to say, IFN-α has anti-virus activity; However, another important feature of the antiviral effect of IFN-α is species specificity, that is to say, IFN-α from a certain species is only effective against viruses infected by that species, but not against viruses infected by other species . For example, human IFN-α is only effective for human virus infection, but not for other species including ...

AI Technical Summary

Problems solved by technology

That is to say, although cyanobacterial proteins have good antiviral activity in vitro, their antiviral applications in vivo have been greatly limited.

At present, it is reported that the antiviral protein of cyanobacteria is used to make vaginal suppositories to prevent and treat HIV infection, and the effect is relatively certain; some people are studying how to reduce its immunogenicity, but there are few practical methods